SAN DIEGO, March  26, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Maze Therapeutics, Inc. (NASDAQ:MAZE). The investigation focuses on Maze&#39;s executive

MAZE

MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Maze Therapeutics Faces Legal Investigation After Sharp Stock Decline

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>SAN DIEGO, March  26, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Maze Therapeutics, Inc. (NASDAQ:MAZE). The investigation focuses on Maze&amp;#39;s executive</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Maze Therapeutics has come under investigation after a 33% stock drop following its Phase 2 trial results for MZE829, which reported a 35.6% reduction in urine albumin-to-creatinine ratio. Johnson Fistel is scrutinizing whether the firm met federal securities laws, potentially impacting investor recovery options.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Maze&#039;s Phase 2 trial results showed a 35.6% improvement in kidney disease.</li><li>The company&#039;s stock fell 33% following the results announcement.</li><li>Johnson Fistel is investigating potential legal claims for investors.</li><li>50% of trial patients saw over 30% decrease in proteinuria.</li><li>Investors may recover losses under federal securities laws.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Maze Therapeutics, Inc. (MAZE)</strong>: Faced significant investor losses and legal scrutiny after trial results.</li><li><strong>Johnson Fistel, PLLP</strong>: Active in investigating possible federal securities laws violations by MAZE.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This news falls under Corporate Developments due to the legal investigation&#039;s potential implications on investor rights and financial stability, highlighting regulatory scrutiny that could significantly impact MAZE&#039;s equity outlook.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Stock price fell 33% after clinical results, reflecting investor loss confidence.</li><li>Ongoing investigation may lead to settlements affecting MAZE&#039;s financials.</li><li>Further news on the trial results could oscillate MAZE&#039;s stock price.</li><li>Investor perception of legal compliance may alter market sentiment quickly.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Maze&#039;s stock price declined 33% on March 25, 2026.</li><li>MZE829 trial showed mean reduction in uACR of 35.6%.</li><li>50% of patients achieved over a 30% decrease in proteinuria.</li><li>Johnson Fistel is investigating potentially recoverable investor losses.</li><li>Investigation focuses on compliance with federal securities laws.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Investors should consider shorting MAZE in the near term amid legal uncertainties.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>SAN DIEGO, March  26, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Maze Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/MAZE">MAZE</a>). The investigation focuses on Maze's executive officers and whether investor losses may be recovered under federal securities laws.</p>  <p><strong>What if I purchased Maze securities?</strong><br></br>If you purchased Maze securities and suffered losses on your investment, join our investigation now: <a href="https://www.globenewswire.com/Tracker?data=W9xZBTIZ2bwNJER-ct-kmEiejfswkXnmjzJDulagw1CzyzGOZ5Emk_w1RosQZAn9UGQabT51u_32jV4R_D8j22oJST1dpDx_ujqQtdQmF8edgwWWt2NOGbnPklb4FaO6QFAYr_Y7MRzLZktn107ITsER6M2juDVAdZnLXSdtlPAeWDUllXXd5Dndl6IOJXEV" rel="nofollow" target="_blank">Click here to join the investigation</a>.<br></br>Or for more information, contact Jim Baker at <a href="mailto:jimb@johnsonfistel.com">jimb@johnsonfistel.com</a> or (619) 814-4471.<br></br>There is no cost or obligation to you.</p>  <p><strong>Background of the investigation</strong><br></br>On March 25, 2026, Maze announced topline results from its Phase 2 HORIZON trial evaluating MZE829 for APOL1-mediated kidney disease. The Company reported a mean reduction in uACR (urine albumin-to-creatinine ratio) of approximately 35.6% at Week 12, with approximately 50% of patients achieving greater than a 30% reduction. The Company characterized these results as "clinically meaningful" and representing initial clinical proof-of-concept.</p>  <p>Following these disclosures, Maze's stock price declined approximately 33% on March 25, 2026.</p>  <p>In light of this disclosure, Johnson Fistel is investigating whether Maze complied with the federal securities laws. If you suffered losses from your investment in Maze stock, contact Johnson Fistel.</p>  <p><strong>About Johnson Fistel, PLLP &#x7C; Securities Fraud &amp; Investor Rights</strong><br></br>Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also assists foreign investors who purchased shares on U.S. exchanges. To learn more, visit <a href="https://www.globenewswire.com/Tracker?data=tdnPmehc6xTrncAjg8aeGevRLeinQ-q4ZrhHHVXF8iEpGXt64U5N-vqmLXHmDu7uWtyQmRPpiLEaVeaVHVqKJPF_CK-XGAHC48prfEoU5sc=" rel="nofollow" target="_blank">www.johnsonfistel.com</a>.</p>  <p><strong>Achievements</strong><br></br>In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services, reflecting the firm's effectiveness in advocating for investors and recovering approximately $90,725,000 for clients in cases where it served as lead or co-lead counsel.</p>  <p>Attorney advertising.<br></br>Past results do not guarantee future outcomes.<br></br>Services may be performed by attorneys in any of our offices.<br></br>Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.</p>  <p><strong>Contact</strong><br></br>Johnson Fistel, PLLP<br></br>501 W. Broadway, Suite 800<br></br>San Diego, CA 92101<br></br>James Baker, Investor Relations – or – Frank J. Johnson, Esq.<br></br>(619) 814-4471 &#x7C; <a href="mailto:jimb@johnsonfistel.com">jimb@johnsonfistel.com</a> &#x7C; <a href="mailto:fjohnson@johnsonfistel.com">fjohnson@johnsonfistel.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY3OTE2MSM3NTA1MjgxIzIxODE3ODk="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/ZjA1NmZkNzMtZjk4My00NzhmLWIzZWMtN2UzZGJkZTI2YTQ5LTExOTMzNTgtMjAyNi0wMy0yNi1lbg==/tiny/Johnson-Fistel-PLLP.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c"><img src="https://ml.globenewswire.com/media/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c/small/johnson-fistel-jpg.jpg" border="0" width="150" height="150" alt="Primary Logo"></img></a></p>

Maze Therapeutics has come under investigation after a 33% stock drop following its Phase 2 trial results for MZE829, which reported a 35.6% reduction in urine albumin-to-creatinine ratio. Johnson Fistel is scrutinizing whether the firm met federal securities laws, potentially impacting investor recovery options.

MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News